Cipla gets approval for generic pamidronate disodium

By: Editor | January 12, 2008

The FDA has given approval to Cipla to sell generic pamidronate disodium, a drug used to treat high blood calcium levels caused by cancer, protecting from bone problems caused by cancer and Paget’s disease of the bone. The drug was sold under the brand Aredia belonging to Novartis but is now off patent. Cipla has got approvals for the 30mg, 60mg and 90mg injection dosages of this drug. There are many generic players in the market; in early November Strides Akorn LLC (a joint venture between Akorn and Strides Arcolabs) too had got FDA approval for this drug. Its release had cited a market of $21mn for the drug. That is a relatively small market for the companies to divide among themselves. Cipla’s share price on Friday, Nov 28 jumped 3.35% to Rs 200, and is up 9% from its level a week ago.

Filed Under:

Companies
Quick News
ANDA
FDA
Generic

More About
Companies
Quick News
FDA
Generic

Johnson Controls to acquire 60% stake in Hitachi Appliances
US-based Johnson Controls and Japan’s Hitachi Appliances have formalised their agreement to form a joint venture that will acquire Hitachi Appliances’ global air-conditioning business. The deal was announced in December 2013 and was to have started operations in 2014, but its closure has stretched all the way till 2015.
Fulford's parent Dashtag rethinks delisting, stock falls by 20%
United Spirits shareholders reject UB group-related transactions

View all Companies Posts →

Johnson Controls to acquire 60% stake in Hitachi Appliances
US-based Johnson Controls and Japan’s Hitachi Appliances have formalised their agreement to form a joint venture that will acquire Hitachi Appliances’ global air-conditioning business. The deal was announced in December 2013 and was to have started operations in 2014, but its closure has stretched all the way till 2015.
UB Engineering: the queer case of a company with no board
Bharti Airtel to transfer data centre business to Nxtra Data for Rs 177 crore

View all Quick News Posts →

Sun Pharma to revise guidance after FDA’s raid on Caraco
Dilip Shanghvi, chairman and managing director, Sun Pharmaceutical Industries, and Sudhir Valia, director held a conference call held to discuss the FDA raid on its US subsidiary Caraco Pharmaceutical Laboratories. This event has come as big blow for Sun. It has withdrawn its current guidance and will issue a revised one, in due course. The issue is expected to have a significant short term impact on Caraco and some adverse impact on Sun’s short term performance too.
FDA sidewinder hits Caraco, Sun Pharma suffers collateral damage
What made the US FDA issue a warning letter to Sun Pharma's subsidiary Caraco?

View all FDA Posts →

EU may relax generics drug transit shipment regulations
India’s dispute with the European Union over the passage of generics drugs through EU territory is close to a resolution, or so it appears. The dispute dates back to 2008 when the EU began seizing drug shipments, of generic drugs being shipped to countries via the EU. India’s position as a leading supplier of generic drugs saw it being one of the worst affected.
Dr Reddy’s and Fujifilm in Japanese generic tie-up
Ranbaxy launches letrozole in UK, Romania and France

View all Generic Posts →

What is the problem with the Indian corporate debt market?

Indian stock markets: round one to the Fed. But is the illness cured?

Comments are closed.

Follow

Subscribe via RSS Follow @ibview

Recent Posts

Reluctance to lower prices a hurdle for growth

The economic value of cutting prices should not be underestimated. In March 2004, Procter & Gamble cut prices of Tide by 47% and Ariel by 28%, challenging Hindustan Lever’s pole position in this market.

Johnson Controls to acquire 60% stake in Hitachi Appliances

US-based Johnson Controls and Japan’s Hitachi Appliances have formalised their agreement to form a joint venture that will acquire Hitachi Appliances’ global air-conditioning business. The deal was announced in December 2013 and was to have started operations in 2014, but its closure has stretched all the way till 2015.

Why the RBI is in no hurry to cut interest rates (in charts)

The RBI is in no hurry to cut interest rates despite inflation trending low for several months now and there being no obvious immediate reason why it should move up sharply. Raghuram Rajan, the RBI governor, may have good reasons to be cautious though, considering what happened during the previous governor D. Subbarao’s tenure.

Fulford’s parent Dashtag rethinks delisting, stock falls by 20%

Fulford (India)’s parent Dashtag, a subsidiary of Merck & Co. has postponed its delisting plans, a decision it has attributed to a sharp rise in Fulford’s share.

United Spirits shareholders reject UB group-related transactions

The relationship between Diageo-controlled United Spirits and the UB group has taken a curious turn. A company meeting called last week to put to vote a number of related material party transactions, saw minority shareholders vote against all UB group-related transactions except for one.

Rajasthan reforms labour laws, will other states follow?

The new Bharatiya Janata Party government in Rajasthan was first off the reform block. Its move to liberalise the state’s labour laws is targeted at attracting more investments by projecting an employer-friendly image.

UB Engineering: the queer case of a company with no board

UB Engineering does not have a board any more as the company announced that its two remaining directors have resigned too. On Thursday, the Vijay Mallya-group engineering company said that Alfred Tuinman, executive director (commercial), had resigned with effect from April 3, 2014.

State Bank of India to raise Rs 11,576 crore equity capital

State Bank of India has got government approval to raise equity capital Rs 11,576 crore in equity capital. SBI said that it will raise Rs 2,000 crore by way of a preferential equity issue to the government, which is its main shareholder, and also raise Rs 9,576 through a qualified institutional placement.

Bharti Airtel to transfer data centre business to Nxtra Data for Rs 177 crore

Bharti Airtel is seeking permission from its shareholders to transfer its data center and managed services (DCMS) business to a subsidiary company. The company’s board had given its permission for the transfer in July.

Market crash-Part II: the RBI and government should join hands

In the previous article, the main problems facing the government and the RBI were listed –a falling rupee, slowing growth and rising inflation. What is needed at this stage is confidence-building measures rather than the fear-inducing steps taken, such as the one imposing capital controls.